Show simple item record

dc.contributor.authorCampbell, Lynn
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-13T09:16:38Z
dc.date.available2010-07-13T09:16:38Z
dc.date.issued2010-06
dc.identifier.citationGefitinib for the treatment of non-small-cell lung cancer. 2010, 11 (8):1343-57 Expert Opin Pharmacotheren
dc.identifier.issn1744-7666
dc.identifier.pmid20426712
dc.identifier.doi10.1517/14656566.2010.481283
dc.identifier.urihttp://hdl.handle.net/10541/107555
dc.description.abstractIMPORTANCE OF THE FIELD: The epidermal growth factor receptor (EGFR) is a leading target for treatment of non-small-cell lung cancer (NSCLC). Recent trials of the small-molecule EGFR inhibitor gefitinib have now more clearly defined indications for usage, and clinical and molecular factors predictive of benefit. AREAS COVERED IN THIS REVIEW: A systematic search of the literature (Medline, ASCO, WCLC meeting abstracts) was performed from January 2000 to January 2010. The Phase III INTEREST study found gefitinib in unselected, pretreated patients was not inferior to docetaxel chemotherapy in overall survival, offering improved quality of life and superior toxicity profile. The Phase III IPASS study demonstrated improved progression-free survival with gefitinib compared with paclitaxel-carboplatin chemotherapy in chemotherapy-naive, never/light ex-smokers with adenocarcinoma histology. Stratifying for EGFR mutation revealed mutation-positive patients had superior outcomes with gefitinib compared with chemotherapy. Subsequent studies (WJOG4305, NEJ002), selecting only EGFR mutation-positive patients prospectively confirm this finding. WHAT THE READER WILL GAIN: The profile of gefitinib and landmark trials in NSCLC are summarized. How biomarkers may further optimize therapeutic benefit is highlighted. TAKE HOME MESSAGE: Gefitinib is expected to have an important impact on management of pretreated and selected chemotherapy-naive patients with advanced NSCLC. In addition, activating EGFR mutations are proven to be of value for prediction of those who will derive most benefit.
dc.language.isoenen
dc.subjectGefitiniben
dc.subjectLung Canceren
dc.subjectMolecular Targeted Therapyen
dc.subjectEpidermal Growth Factor Receptoren
dc.titleGefitinib for the treatment of non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Foundation Trust, Medical Oncology, Wilmslow Road, Manchester, UK. lrcampbell@doctors.org.uken
dc.identifier.journalExpert Opinion on Pharmacotherapyen
html.description.abstractIMPORTANCE OF THE FIELD: The epidermal growth factor receptor (EGFR) is a leading target for treatment of non-small-cell lung cancer (NSCLC). Recent trials of the small-molecule EGFR inhibitor gefitinib have now more clearly defined indications for usage, and clinical and molecular factors predictive of benefit. AREAS COVERED IN THIS REVIEW: A systematic search of the literature (Medline, ASCO, WCLC meeting abstracts) was performed from January 2000 to January 2010. The Phase III INTEREST study found gefitinib in unselected, pretreated patients was not inferior to docetaxel chemotherapy in overall survival, offering improved quality of life and superior toxicity profile. The Phase III IPASS study demonstrated improved progression-free survival with gefitinib compared with paclitaxel-carboplatin chemotherapy in chemotherapy-naive, never/light ex-smokers with adenocarcinoma histology. Stratifying for EGFR mutation revealed mutation-positive patients had superior outcomes with gefitinib compared with chemotherapy. Subsequent studies (WJOG4305, NEJ002), selecting only EGFR mutation-positive patients prospectively confirm this finding. WHAT THE READER WILL GAIN: The profile of gefitinib and landmark trials in NSCLC are summarized. How biomarkers may further optimize therapeutic benefit is highlighted. TAKE HOME MESSAGE: Gefitinib is expected to have an important impact on management of pretreated and selected chemotherapy-naive patients with advanced NSCLC. In addition, activating EGFR mutations are proven to be of value for prediction of those who will derive most benefit.


This item appears in the following Collection(s)

Show simple item record